Capital Research Global Investors
BEAM icon

Capital Research Global Investors’s Beam Therapeutics BEAM Stock Holding History

Capital Research Global Investors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-491,882
Closed -$15.1M – 418
2023
Q1 		$15.1M Buy
491,882
+264,316
+116% +$10.4M ﹤0.01% 380
2022
Q4 		$8.9M Buy
+227,566
New +$10.2M ﹤0.01% 402

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors's BEAM Position: Q2 2023 in Review

Capital Research Global Investors sold out of Beam Therapeutics (BEAM) in Q2 2023, closing a stake of 491,882 shares — an estimated $15.1M sold.

Capital Research Global Investors first reported a position in BEAM in Q4 2022 and held it in 2 quarters. The position peaked at $15.1M in Q1 2023. 194 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

  • Capital Research Global Investors reported no remaining Beam Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Capital Research Global Investors sold 491,882 Beam Therapeutics shares in Q2 2023, an estimated $15.1M.
  • Capital Research Global Investors first reported a position in Beam Therapeutics in Q4 2022 and held it in 2 quarters.
  • Capital Research Global Investors's Beam Therapeutics position peaked at $15.1M in Q1 2023.
  • 194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Capital Research Global Investors's 13F filing for Q2 2023, filed 11 Aug 2023.